We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

Stress, Diurnal Cortisol, and Breast Cancer Survival

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2012 by Stanford University.
Recruitment status was:  Active, not recruiting
ClinicalTrials.gov Identifier:
First Posted: September 27, 2005
Last Update Posted: November 14, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
National Institute on Aging (NIA)
Information provided by (Responsible Party):
Stanford University
The purpose of this study is to learn about the effects of stress on hormones, the relationship between these hormones and cancer progression.

Condition Intervention
Breast Cancer Drug: Sandostatin

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Stress, Diurnal Cortisol, and Breast Cancer Survival

Resource links provided by NLM:

Further study details as provided by Stanford University:

Biospecimen Retention:   Samples Without DNA

Estimated Enrollment: 115
Study Start Date: September 2002
Estimated Study Completion Date: December 2012
Primary Completion Date: November 2004 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Sandostatin
    Calculated per patient
    Other Names:
    • Octreotide
    • Octreo
Detailed Description:
The purpose of this study is to investigate stress and tonic activation of diurnal cortisol in aging metastatic breast cancer patients; feedback inhibition & activation of cortisol; and stress-induced phasic activation of cortisol.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   35 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients with recurrent or metastatic breast cancer

Inclusion Criteria:

  1. Diagnosis of recurrent or metastatic breast cancer.
  2. Karnofsky of 70% or greater.
  3. Proficient enough in English to be able to take questionnaires and participate in the required tasks.
  4. Living within the Greater Bay Area.
  5. Age 35 or older .

Exclusion Criteria:

  1. Positive supraclavicular lymph nodes as the only metastatic lesion at the time of initial diagnosis.
  2. Active cancers within the past 10 years other than breast cancer, basal cell or squamous cell carcinomas of the skin, or in situ cancer of the cervix.
  3. Any other serious medical condition that will effect short term survival
  4. History of major psychiatric illness for which patient was hospitalized or medicated, with the exception of depression or anxiety
  5. A diagnosis of diabetes.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00226967

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
National Institute on Aging (NIA)
Principal Investigator: David Spiegel Stanford University
  More Information

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT00226967     History of Changes
Other Study ID Numbers: BRSADJ0006
76389 ( Other Identifier: Stanford University Alternate IRB Approval Number )
BRSADJ0006 ( Other Identifier: Stanford University )
12273 ( Other Identifier: Stanford IRB )
First Submitted: September 13, 2005
First Posted: September 27, 2005
Last Update Posted: November 14, 2012
Last Verified: November 2012

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Anti-Inflammatory Agents
Gastrointestinal Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents